Zevra Therapeutics Inc. (ZVRA) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Zevra Therapeutics Inc. stock (ZVRA) is currently trading at $9.13. Zevra Therapeutics Inc. PE ratio is 6.78. Zevra Therapeutics Inc. PS ratio (Price-to-Sales) is 5.05. Analyst consensus price target for ZVRA is $22.78. WallStSmart rates ZVRA as Hold.
- ZVRA PE ratio analysis and historical PE chart
- ZVRA PS ratio (Price-to-Sales) history and trend
- ZVRA intrinsic value — DCF, Graham Number, EPV models
- ZVRA stock price prediction 2025 2026 2027 2028 2029 2030
- ZVRA fair value vs current price
- ZVRA insider transactions and insider buying
- Is ZVRA undervalued or overvalued?
- Zevra Therapeutics Inc. financial analysis — revenue, earnings, cash flow
- ZVRA Piotroski F-Score and Altman Z-Score
- ZVRA analyst price target and Smart Rating
Zevra Therapeutics Inc.
📊 No data available
Try selecting a different time range
ZVRA Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · Zevra Therapeutics Inc. (ZVRA)
ZVRA is trading near its Graham intrinsic value of $9.18, suggesting the stock is reasonably priced at current levels.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
Zevra Therapeutics Inc. (ZVRA) · 9 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in return on equity, operating margin, revenue growth. Concerns around peg ratio. Fundamentals are solid but monitor weak areas for improvement.
Zevra Therapeutics Inc. (ZVRA) Key Strengths (5)
Every $100 of shareholder equity generates $86 in profit
Revenue surging 183.40% year-over-year
Keeps $78 of every $100 in revenue as net profit
Strong operational efficiency: $27 kept per $100 revenue
65.73% held by institutions, strong professional interest
Supporting Valuation Data
Zevra Therapeutics Inc. (ZVRA) Areas to Watch (4)
Very expensive relative to growth, significant premium
Premium valuation at 5.0x annual revenue
Premium pricing at 3.5x book value
Small-cap company with higher risk but more growth potential
Supporting Valuation Data
Zevra Therapeutics Inc. (ZVRA) Detailed Analysis Report
Overall Assessment
This company scores 60/100 in our Smart Analysis, earning a C grade. Out of 9 metrics analyzed, 5 register as strengths (avg 9.2/10) while 4 fall into concern territory (avg 3.8/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Return on Equity, Revenue Growth, Profit Margin. Profitability is solid with Return on Equity at 85.70%, Operating Margin at 27.30%, Profit Margin at 78.20%. Growth metrics are encouraging with Revenue Growth at 183.40%.
The Bear Case
The primary concerns are PEG Ratio, Price/Sales, Price/Book. Some valuation metrics including PEG Ratio (10.67), Price/Sales (5.05), Price/Book (3.51) suggest expensive pricing.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether PEG Ratio improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at 85.70% currently healthy but needing to be sustained. Third, growth sustainability, with Revenue Growth at 183.40% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a moderate-to-high risk investment. The weight of evidence leans positive, with more strengths than concerns. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Mixed fundamentals with both positives (Return on Equity, Revenue Growth) and negatives (PEG Ratio, Price/Sales). A cautious approach is warranted. Monitor for improvement in weak areas before increasing conviction.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
ZVRA Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
ZVRA's Price-to-Sales ratio of 5.05x trades at a deep discount to its historical average of 18.51x (14th percentile). The current valuation is 92% below its historical high of 60.46x set in Jun 2021, and 516% above its historical low of 0.82x in May 2020. Over the past 12 months, the PS ratio has compressed from ~18.7x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for Zevra Therapeutics Inc. (ZVRA) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Zevra Therapeutics Inc. is a strong growth company balancing expansion with improving profitability. Revenue reached 106M with 183% growth year-over-year. Profit margins are strong at 78.2%, reflecting pricing power and operational efficiency.
Key Findings
Revenue growing at 183% YoY, reaching 106M. This pace significantly outperforms most BIOTECHNOLOGY peers.
ROE of 85.7% means the company generates strong returns on shareholder equity. Above 20% is considered top-tier.
What to Watch Next
Growth sustainability: can Zevra Therapeutics Inc. maintain 183%+ revenue growth, or will competition slow it down?
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Zevra Therapeutics Inc..
Bottom Line
Zevra Therapeutics Inc. offers an attractive blend of growth (183% revenue expansion) and improving fundamentals. The company is transitioning from pure growth to profitable growth, a critical inflection point. Watch for sustained margin expansion as the key signal.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Zevra Therapeutics Inc.(ZVRA)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Zevra Therapeutics, Inc., a rare disease company melding science, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company is headquartered in Celebration, Florida.